Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 15/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 14/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4344633 | 0.82 | OPRL1 (0.49) | OPRM1OPRL1KDM1ASLC6A2SLC6A4 | |
| SCHEMBL3144057 | 0.82 | OPRL1 (0.62) | OPRM1OPRL1 | |
| SCHEMBL316598 | 0.81 | OPRL1 (0.66) | OPRM1OPRL1KDM1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL5572136 | 0.79 | OPRL1 (0.64) | OPRM1OPRL1KDM1ASLC6A2SLC6A4 | |
| SCHEMBL3411718 | 0.78 | OPRL1 (0.51) | OPRM1OPRL1KDM1ASLC6A2SLC6A4 | |
| SCHEMBL2985663 | 0.78 | OPRM1 (0.51) | OPRM1OPRL1KDM1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL5572132 | 0.77 | OPRM1 (0.50) | OPRM1OPRL1KDM1ASLC6A2SLC6A4 | |
| SCHEMBL4344782 | 0.77 | SLC6A4 (0.62) | OPRM1OPRL1KDM1ASLC6A2SLC6A4 | |
| SCHEMBL517439 | 0.76 | OPRL1 (0.50) | OPRM1OPRL1KDM1ASLC6A2SLC6A4 | |
| SCHEMBL5160213 | 0.74 | OPRM1 (0.50) | OPRM1OPRL1KDM1ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502907-B1 | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2018-08-29 | — | — | EP | disclosed |
| EP-2518052-B1 | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2017-12-20 | — | — | EP | disclosed |
| EP-2271613-B1 | HYDROXYMETHYLCYCLOHEXYLAMINES | GRUENENTHAL GMBH (DE) | 2014-06-18 | — | — | EP | disclosed |
| EP-2260021-B1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-04-23 | — | — | EP | disclosed |
| EP-2518052-A1 | Substituted 4-aminocyclohexane derivatives | Grünenthal GmbH (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-8288406-B2 | Hydroxymethylcyclohexylamines | GRUENENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-2502907-A1 | Substituted 4-aminocyclohexane derivatives | Grünenthal GmbH (DE) | 2012-09-26 | — | — | EP | disclosed |
| US-20110059999-A1 | Hydroxymethylcyclohexylamines | Grünenthal GmbH (DE) | 2011-03-10 | — | — | US | disclosed |
| EP-2271613-A1 | HYDROXYMETHYLCYCLOHEXYL AMINES | Grünenthal GmbH (DE) | 2011-01-12 | — | — | EP | disclosed |
| EP-2260021-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009118171-A1 | HYDROXYMETHYLCYCLOHEXYL AMINES | Grünenthal GmbH (DE) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009118168-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059999-A1 | Hydroxymethylcyclohexylamines | OPRL1, OPRM1, OPRD1 | OPRM1 2/4885OPRL1 1/4885KDM1A 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.